Fri, Apr 18, 2014, 2:09 AM EDT - U.S. Markets closed for Good Friday


% | $
Quotes you view appear here for quick access.

Nektar Therapeutics (NKTR) Message Board

  • gladpick gladpick Jun 4, 2008 9:08 AM Flag

    Lehman's update

    "Nektar Therapeutics (NKTR - US$ 4.49) 1-Overweight Specialty Pharmaceuticals
    Company Update
    NKTR-102 Gains Some Deserved Visibility

    Investment Conclusion

    • We continue to expect increased investor
    appreciation for Nektar's growing proprietary
    pipeline, in particular NKTR-102, given its
    promising, albeit, early-stage trial results &
    potential broad spectrum of tumor targets. While
    this appreciation may take some time, we believe
    that current valuation translates to an attractive
    risk/reward profile.

    • Yesterday, Nektar announced positive Phase 1
    results for NKTR-102 (PEG- irinotecan) in
    advanced cancer patients whose cancers have
    advanced on other therapies.
    • Most encouraging to us were comments made by
    the lead investigator of the Phase 1 trial, who
    stated that response rates were well above the 4%
    level typical of single compounds in Phase 1, with
    repeat evidence of activity in a number of different
    tumor types.
    • Nektar also announced plans for a Phase 2 study
    for NKTR-102 in a subset of advanced colorectal
    cancer patients, a Phase 2 trial in metastatic
    breast cancer & another in platinum-resistant
    ovarian cancer, all expected to begin in 2H08.
    Stock Rating Target Price

    New: 1-Overweight New: US$ 9.00 "

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • gladpick - Thanks for posting the Lehman research piece. I found the following statement particularly telling:

      "Most encouraging to us were comments made by the lead investigator of the Phase 1 trial"

      Dr. Von Hoff was blunt with his optimism based on what he had personally seen with patients whose cancer responded positively to NKTR-102 after failing on existing approved drugs. Dr. Von Hoff also did not hedge his opinion that the likelihood of NKTR-102 ultimately being approved is high. This is a guy who has been involved in clinical testing of many cancer drugs that have been approved and have gone on to commercial success. I think he's an asset to Nektar in terms of helping determine the best course of action to gain approval of NKTR-102 as well as being a respected voice to potential partners and the investment community.

      One comment that Dr. Von Hoff made that I found interesting was that 80% of cancer drugs are prescribed for off label indications. This number surprised me. I wonder how the oncologists who do this get around the liability of prescribing drugs that haven't been approved by the FDA for these off-label indications?

      Good luck to NKTR longs.

10.97-0.07(-0.68%)Apr 17 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Weibo Corporation
NasdaqGSThu, Apr 17, 2014 4:00 PM EDT
SandRidge Energy, Inc.
NYSEThu, Apr 17, 2014 4:01 PM EDT